



**Association between single nucleotide polymorphisms in the antioxidant genes CAT, GR and SOD1, erythrocyte enzyme activities, dietary and life style factors and breast cancer risk in a Danish, prospective cohort study**

Kopp, Tine Iskov; Vogel, Ulla; Dragsted, Lars Ove; Tjønneland, Anne; Ravn-Haren, Gitte

*Published in:*  
OncoTarget

*DOI:*  
[10.18632/oncotarget.18062](https://doi.org/10.18632/oncotarget.18062)

*Publication date:*  
2017

*Document version*  
Publisher's PDF, also known as Version of record

*Document license:*  
[CC BY](#)

*Citation for published version (APA):*  
Kopp, T. I., Vogel, U., Dragsted, L. O., Tjønneland, A., & Ravn-Haren, G. (2017). Association between single nucleotide polymorphisms in the antioxidant genes CAT, GR and SOD1, erythrocyte enzyme activities, dietary and life style factors and breast cancer risk in a Danish, prospective cohort study. *OncoTarget*, 8(38), 62984-62997. <https://doi.org/10.18632/oncotarget.18062>

# Association between single nucleotide polymorphisms in the antioxidant genes *CAT*, *GR* and *SOD1*, erythrocyte enzyme activities, dietary and life style factors and breast cancer risk in a Danish, prospective cohort study

Tine Iskov Kopp<sup>1,2,3</sup>, Ulla Vogel<sup>4</sup>, Lars Ove Dragsted<sup>5</sup>, Anne Tjønneland<sup>2</sup> and Gitte Ravn-Haren<sup>3</sup>

<sup>1</sup>Research Centre for Prevention and Health, Glostrup, Denmark

<sup>2</sup>Danish Cancer Society Research Center, Copenhagen, Denmark

<sup>3</sup>National Food Institute, Technical University of Denmark, Søborg, Denmark

<sup>4</sup>National Research Centre for the Working Environment, Copenhagen, Denmark

<sup>5</sup>Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark

**Correspondence to:** Tine Iskov Kopp, **email:** TINKOP@rkkp.dk

**Keywords:** breast cancer, prospective cohort study, single nucleotide polymorphisms, gene-environment interactions, antioxidant enzymes

**Received:** December 14, 2016

**Accepted:** April 10, 2017

**Published:** May 22, 2017

**Copyright:** Kopp et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## ABSTRACT

**Exposure to estrogens and alcohol consumption - the two only well-established risk factors for breast cancer - are capable of causing oxidative stress, which has been linked to progression of breast cancer. Here, five functional polymorphisms in the antioxidant genes *SOD1*, *CAT* and *GSR* were investigated in 703 breast cancer case-control pairs in the Danish, prospective "Diet, Cancer and Health" cohort together with gene-environment interactions between the polymorphisms, enzyme activities and intake of fruits and vegetables, alcohol and smoking in relation to breast cancer risk. Our results showed that genetically determined variations in the antioxidant enzyme activities of *SOD1*, *CAT* and *GSR* were not associated with risk of breast cancer *per se*. However, intake of alcohol, fruit and vegetables, and smoking status interacted with some of the polymorphisms in relation to breast cancer risk. Four polymorphisms were strongly associated with enzyme activity, but there was no interaction between any of the studied environmental factors and the polymorphisms in relation to enzyme activity. Additionally, single measurement of enzyme activity at entry to the cohort was not associated with risk of breast cancer. Our results therefore suggest that the antioxidant enzyme activities studied here are not major determinants of breast cancer risk.**

## INTRODUCTION

Breast cancer (BC) is the most common type of cancer in Denmark among women and the second leading cause of cancer death after lung cancer [1]. The incidence has increased during the last decade [1], which warrants further knowledge about the underlying mechanisms. Environmental factors, in interplay with genetics, are known to be important in the etiology of BC [2–5]. Therefore,

examining gene-environment interactions is an effective tool for identifying biological pathways in disease etiology.

The only well-established risk factors for BC are associated with prolonged exposure to estrogens [6,7] and alcohol consumption [8–10]. Both exposure to estrogens and alcohol consumption are capable of causing oxidative stress [reviewed in 11], which has also been linked to progression of cancer, including BC [12–18]. Oxidative stress is caused by an imbalance between the generation of reactive oxygen species (ROS), such as superoxide anions, hydrogen

peroxide and hydroxyl radicals, and the antioxidant defense, including various enzymes and high and low molecular weight antioxidants (including glutathione (GSH)), leading to DNA damage, lipid peroxidation and protein oxidation. An efficient antioxidant defense will limit oxidative damage by ensuring a reducing environment [19,20]. The enzymatic antioxidant defense system is complex and may be described as an interacting network of several enzymes, including glutathione reductase (GR), superoxide dismutase (SOD) and catalase (CAT). Where GR catalyzes the reduction of GSH, an important antioxidant, superoxide anion radicals are dismutated by SOD to hydrogen peroxide. CAT converts hydrogen peroxide to water and oxygen, thereby preventing formation of the highly reactive hydroxyl radical. BC may partly be caused by oxidative damage combined with a failure of antioxidants to protect the breast tissue [14]. Smoking and alcohol consumption are sources of ROS whereas fruit and vegetables are rich in dietary antioxidants. Furthermore, several studies have indicated that an increased intake of fruits and vegetables may affect the enzymatic antioxidant defense system, leading to increased enzyme activities [21–24]. These dietary and life style choices may modulate risk of BC by altering the level of oxidative stress, such that alcohol consumption and smoking increase the risk, while intake of fruit and vegetables decreases the risk. However, where meta-analyses have not provided consisting evidence of an inverse association between intake of fruit and vegetables and BC risk on one side [25–29], and positive association between smoking and BC risk on the other side [reviewed in 30], interactions between smoking, alcohol consumption, fruit and vegetable intake, and polymorphisms in antioxidant genes in relation to BC risk, have been reported [30–34]. Thus, genetically determined variations in the activities of enzymes that protect against or generate oxidative stress could modify associations between dietary antioxidants and exogenous sources of ROS, and BC risk, and thus explain some of the inconsistencies in the results from these studies. Additionally, lower antioxidant enzyme activities in BC patients compared to healthy controls have been reported in several studies [35–38]. Prospective cohort studies may reveal whether these lowered activities are a cause or consequence of the disease in combination with examination of dietary and life style factors and their interaction with the enzymes in relation to risk of disease.

Functional polymorphisms may impact the enzymatic activities leading to altered antioxidant defense and thereby affect disease risk and health. We have previously found associations between functional polymorphisms in *GPX1* and *GPX4* genes, erythrocyte GPX activity, alcohol intake, hormone replacement therapy (HRT) use and BC risk in the Danish “Diet, Cancer and Health” (DCH) cohort [31,39]. In the present study, we wanted to extend these findings with polymorphisms in the antioxidant genes *SOD1* (encoding SOD), *CAT* (encoding CAT) and *GSR* (encoding GR) in a study group of 975 postmenopausal women with BC and 975 matched controls nested within the DCH cohort;

and search for gene-environment interactions between the polymorphisms, enzyme activities and intake of fruits and vegetables, alcohol and smoking in relation to BC risk.

## RESULTS

Baseline characteristics of BC cases and matched controls are presented in Table 1. Findings regarding the included risk factors have been reported previously for the whole DCH cohort, for a subset of the present study, and for the present study group [31,40–47]. Among controls, the genotype distribution of the polymorphisms did not deviate from Hardy-Weinberg equilibrium (results not shown). None of the polymorphisms were significantly associated with risk of BC *per se* (Table 2); however, a tendency towards increased risk among variant carriers of the *SOD1*/rs202445 polymorphism, was observed ( $P=0.06$ ). Only *GSR*/rs1002149 interacted weakly with alcohol intake in relation to risk of BC such that variant T-carriers had a 24% increased risk of BC per 10 g alcohol/day (95% CI: 1.09-1.42), whereas wild-type GG-carriers did not display alcohol-related modification of BC risk ( $P$ -value for interaction ( $P_{\text{int}}$ )= 0.048) (Table 3). We also found interaction between *SOD1*/rs202445 and intake of fruits and vegetables in relation to risk of BC ( $P_{\text{int}}$ =0.016) (Table 4). Carriage of the variant G-allele of *SOD1*/rs202445 was associated with a 13% increased risk of BC (95% CI: 1.03-1.25), whereas wild-type AA-carriers showed no modified risk of BC per 100 g fruits and vegetables per day (Table 4). Smoking status interacted with the *CAT*/rs1001179 polymorphism in relation to risk of BC ( $P_{\text{int}}$ =0.0015) (Table 5). Variant A-carriers of the polymorphism, who did not smoke, had a 41% increased risk of BC (95% CI: 1.07-1.87) compared to non-smoking wild-type GG-carriers (Table 5).

Activities of CAT, SOD and GR enzymes were measured in a subset of the cohort at the time of entry into the DCH cohort ( $n=434$  cases and 434 controls). In linear analysis (Table 6), increment in enzyme activity of the three enzymes was associated with statistically non-significant decreased risk of BC ( $\text{IRR}_{\text{CAT}}=0.89$ , 95% CI: 0.75-1.06;  $\text{IRR}_{\text{SOD}}=0.94$ , 95% CI: 0.79-1.12;  $\text{IRR}_{\text{GR}}=0.83$ , 95% CI: 0.68-1.02). However, in the tertile analyses of the enzyme activity (Table 6), only increasing CAT activity exhibited a dose-dependent decrease in BC risk. In Table 7, the correlation between intake of fruit and vegetables, alcohol and smoking, and enzyme activity was investigated. A negative correlation between alcohol intake and GR activity was found ( $P=0.043$ ) (Table 7). Smoking and intake of alcohol were positively correlated with SOD activity with marginally statistical significance ( $P_{\text{alcohol}}=0.050$  and  $P_{\text{present smokers}}=0.054$ ) (Table 7). None of the investigated lifestyle factors were associated with CAT activity. In Table 8, the relation between the studied genotypes and

**Table 1: Baseline characteristics of the DCH study participants by selected demographic and established BC risk factors**

Variable	Cases		Controls		IRR <sup>a</sup> (95% CI)
	n (%)	Median (5-95%)	n (%)	Median (5-95%)	
Women	703 (100)		703 (100)		
Age at inclusion, years		57 (51-64)		57 (51-64)	
School education					
Short	206 (29)		250 (36)		1.0 (ref.)
Medium	353 (50)		313 (45)		1.19 (0.92-1.54)
Long	144 (20)		122 (17)		1.27 (0.90-1.78)
Body mass index, kg/m <sup>2</sup>		25 (20-34)		25 (20-34)	1.02 (0.97-1.08) <sup>b</sup>
Nulliparous	104 (15)		82 (12)		1.02 (0.65-1.58) <sup>c</sup>
Number of births		2 (1-4)		2 (1-4)	0.92 (0.79-1.05)
Age at first birth, years		24 (18-31)		23 (18-32)	1.06 (0.91-1.24) <sup>d</sup>
Use of HRT, years <sup>e</sup>		6 (0.5-20)		5 (0.5-20)	1.00 (0.87-1.15) <sup>f</sup>
Abstainers	18 (3)		22 (3)		0.92 (0.47-1.79) <sup>g</sup>
Alcohol intake, g/day		11 (1-43)		9 (1-40)	1.11 (1.03-1.20) <sup>h</sup>
Present smokers	241 (34)		264 (38)		0.93 (0.73-1.19)
Total fruit and vegetable intake, g/day		361 (118-785)		349 (108-819)	1.02 (0.97-1.08) <sup>i</sup>
Benign breast disease	139 (20)		88 (13)		1.64 (1.22-2.20)

Values are expressed as medians (5th and 95th percentiles) or as fractions (%). IRR: incidence rate ratio.

<sup>a</sup> The risk estimates for BC are mutually adjusted.

<sup>b</sup> The risk is estimated per additional 2 kg/m<sup>2</sup>.

<sup>c</sup> The risk is estimated for nulliparous versus one birth at age 35.

<sup>d</sup> The risk is estimated per additional 5 years.

<sup>e</sup> Among ever users of HRT.

<sup>f</sup> The risk is estimated per additional 5-year of HRT use.

<sup>g</sup> The risk for abstainers compared to the increment of 10 g alcohol per day.

<sup>h</sup> Among drinkers, risk estimate is estimated for the increment of 10 g alcohol per day.

<sup>i</sup> The risk is estimated per additional 100 g intake fruit and vegetables per day.

enzyme activities was examined. *CAT*/rs1001179, *CAT*/rs12270780 and *GSR*/rs1002149 polymorphisms were strongly associated with enzyme activities ( $P \leq 0.0001$  for all three single nucleotide polymorphisms (SNPs)) among both cases and controls, so that enzyme activities increased for each variant allele for *CAT*/rs12270780 and *GSR*/rs1002149, whereas enzyme activities decreased for *CAT*/rs1001179 for each variant allele (Table 8). *CAT*/rs769217 polymorphism was also associated with enzyme activity ( $P_{\text{all}} = 0.0007$ ) with enzyme activities decreasing for each variant allele, but only among controls ( $P_{\text{controls}} = 0.0007$  and  $P_{\text{cases}} = 0.25$ ) (Table 8). These associations were not significantly modified by intake of alcohol, fruits and vegetables, and smoking status ( $P_{\text{int}}$  between 0.26-0.92 (Supplemental Table 1)). We have previously found association between HRT use and GPX activity [39], but in the

present study, we did not find indication of association between *CAT*, *SOD* or *GR* enzyme activities and HRT use (Supplemental Table 2). Haplotype analysis of *CAT* polymorphisms revealed that haplotypes encompassing variant alleles of *CAT*/rs1001179 and *CAT*/rs769217, respectively, were functional, and that haplotypes encompassing the variant allele of *CAT*/rs1001179 had the strongest effect on *CAT* enzyme activity (Table 9).

We found an increased risk of BC among women carrying both the low activity A-allele of *CAT*/rs1001179 and high activity G-allele of *SOD1*/rs202445 (IRR: 1.43; 95% CI: 1.01-2.01) (Table 10). The interaction was, however, not significant on a multiplicative scale ( $P_{\text{int}} = 0.27$ ), but could be considered additive. We also investigated other combinations of polymorphisms in relation to risk of BC, but did not find anything further (results not shown).

**Table 2: IRR for BC in relation to the studied polymorphisms**

Gene	SNP	n <sub>cases</sub> (%) (n=703)	n <sub>controls</sub> (%) (n=703)	IRR <sup>a</sup> (95% CI)	IRR <sup>b</sup> (95% CI)	P-value <sup>c</sup>
<i>CAT</i>	rs1001179					
	GG	408 (58)	409 (58)	1.00 (ref.)	1.00 (ref.)	
	GA	251 (36)	253 (36)	1.00 (0.81-1.25)	1.05 (0.87-1.32)	0.65
	AA	44 (6)	41 (6)	1.08 (0.69-1.70)	1.07 (0.67-1.70)	0.79
	GA+AA	295 (42)	294 (42)	1.02 (0.83-1.25)	1.06 (0.85-1.31)	0.62
<i>CAT</i>	rs12270780					
	GG	393 (56)	405 (58)	1.00 (ref.)	1.00 (ref.)	
	GA	267 (38)	267 (38)	1.02 (0.82-1.27)	1.01 (0.80-1.26)	0.96
	AA	43 (6)	31 (4)	1.37 (0.85-2.19)	1.29 (0.80-2.09)	0.30
	GA+AA	310 (44)	298 (42)	1.06 (0.86-1.31)	1.04 (0.84-1.29)	0.73
<i>CAT</i>	rs769217					
	CC	454 (65)	460 (65)	1.00 (ref.)	1.00 (ref.)	
	CT	222 (32)	211 (30)	1.06 (0.84-1.34)	1.06 (0.83-1.35)	0.64
	TT	27 (4)	32 (5)	0.87 (0.50-1.51)	0.97 (0.55-1.71)	0.91
	CT+TT	249 (35)	243 (35)	1.04 (0.83-1.30)	1.05 (0.83-1.32)	0.69
<i>GSR</i>	rs1002149					
	GG	480 (68)	452 (64)	1.00 (ref.)	1.00 (ref.)	
	GT	201 (29)	225 (32)	0.85 (0.68-1.06)	0.86 (0.68-1.09)	0.21
	TT	22 (3)	26 (4)	0.80 (0.44-1.45)	0.84 (0.46-1.55)	0.58
	GT+TT	223 (32)	251 (36)	0.84 (0.68-1.05)	0.86 (0.69-1.08)	0.19
<i>SOD1</i>	rs202445					
	AA	460 (65)	490 (70)	1.00 (ref.)	1.00 (ref.)	
	AG	214 (30)	193 (27)	1.18 (0.93-1.50)	1.22 (0.96-1.56)	0.11
	GG	29 (4)	20 (3)	1.56 (0.86-2.80)	1.55 (0.85-2.84)	0.15
	AG+GG	243 (35)	213 (30)	1.22 (0.97-1.53)	1.25 (0.99-1.59)	0.06

IRR: incidence rate ratio.

<sup>a</sup> Crude.<sup>b</sup> Adjusted for parous/nulliparous, number of births, age at first birth, length of school education (low, medium, high), duration of HRT use (years), BMI (kg/m<sup>2</sup>), previous benign breast disease and alcohol intake (10 g/day).<sup>c</sup> P-value for the adjusted risk estimates.

## DISCUSSION

In the present study, we found that genetically determined variations in the antioxidant enzyme activities of *CAT*, *GSR* and *SOD1* were not associated with risk of BC *per se* in this relatively large cohort. However, intake of alcohol, fruit and vegetables, and smoking status interacted with some of the polymorphisms in relation to BC risk. All polymorphisms, except for *SOD1*/rs202445, were associated with enzyme activity, but there was no interaction between any of the studied environmental factors and polymorphisms in relation to enzyme activity. Haplotype analysis of *CAT* polymorphisms revealed that *CAT*/rs1001179 had the strongest effect on CAT enzyme activity. Additionally, single measurement of enzyme activity at entry to the cohort was not associated with risk of BC.

Both *in vivo* [48–50] and *in vitro* [49] studies have shown that alcohol is capable of decreasing GR activity and protein levels in rat breast [48], liver [49] and brain tissue [50]. The present study supports these findings, since intake of alcohol is associated with decreased overall GR enzyme activity and increased risk of BC among carriers of the high activity T-variant allele of the *GSR*/rs1002149 polymorphism. Carriage of the variant allele of this polymorphism is associated with statistically non-significant decreased risk of BC *per se*, indicating that alcohol may inhibit GR activity in the variant enzyme. However, alcohol did not interact with *GSR*/rs1002149 in relation to enzyme activity in the present study. It is well-known that alcohol consumption increases oxidative stress [51,52] and *in vitro* studies have shown that acetaldehyde (the product of the first step in alcohol oxidation) can interact with GSH spontaneously [53] (forming a GSH-acetaldehyde conjugate). Although



**Table 3: IRR for BC in relation to the studied polymorphisms per increment of 10 g alcohol per day among current drinkers<sup>a</sup>**

Gene	SNP	n <sub>cases</sub> (%) (n=664)	n <sub>controls</sub> (%) (n=664)	IRR <sup>b</sup> (95% CI)	IRR <sup>c</sup> (95% CI)	P-value <sup>d</sup>
CAT	rs1001179					
	GG	382 (58)	388 (58)	1.16 (1.05-1.27)	1.15 (1.04-1.26)	0.43
	GA+AA	282 (42)	276 (42)	1.09 (0.96-1.24)	1.07 (0.94-1.22)	
CAT	rs12270780					
	GG	375 (56)	384 (58)	1.12 (1.02-1.23)	1.11 (1.00-1.22)	0.77
	GA+AA	289 (44)	280 (42)	1.15 (1.02-1.30)	1.13 (1.00-1.28)	
CAT	rs769217					
	CC	430 (65)	434 (65)	1.17 (1.06-1.29)	1.15 (1.04-1.27)	0.34
	CT+TT	234 (35)	230 (35)	1.08 (0.96-1.21)	1.07 (0.95-1.20)	
GSR	rs1002149					
	GG	456 (69)	424 (64)	1.06 (0.97-1.17)	1.05 (0.96-1.16)	0.048
	GT+TT	208 (31)	240 (36)	1.27 (1.12-1.45)	1.24 (1.09-1.42)	
SOD1	rs202445					
	AA	436 (66)	463 (70)	1.15 (1.06-1.26)	1.14 (1.04-1.25)	0.42
	AG+GG	228 (34)	201 (30)	1.08 (0.94-1.24)	1.06 (0.92-1.23)	

IRR: incidence rate ratio.

<sup>a</sup> 39 case-control pairs were excluded from this analysis due to one participant (or both) in the case-control pair was/(were) abstainer(s).

<sup>b</sup> Crude.

<sup>c</sup> Adjusted for parity (parous/nulliparous, number of births, age at first birth), length of school education (low, medium, high), duration of HRT use (years), previous benign breast disease and BMI (kg/m<sup>2</sup>) at baseline.

<sup>d</sup> P-value for interaction for adjusted risk estimates.

**Table 4: IRR for BC in relation to the studied polymorphisms per increment of 100 g fruit and vegetables per day**

Gene	SNP	n <sub>cases</sub> (%) (n=703)	n <sub>controls</sub> (%) (n=703)	IRR <sup>a</sup> (95% CI)	IRR <sup>b</sup> (95% CI)	P-value <sup>c</sup>
CAT	rs1001179					
	GG	408 (58)	409 (58)	1.00 (0.93-1.07)	1.00 (0.93-1.07)	0.32
	GA+AA	295 (42)	294 (42)	1.05 (0.98-1.13)	1.05 (0.98-1.13)	
CAT	rs12270780					
	GG	393 (56)	405 (58)	1.02 (0.95-1.08)	1.01 (0.94-1.07)	0.33
	GA+AA	310 (44)	298 (42)	1.04 (0.97-1.12)	1.06 (0.98-1.14)	
CAT	rs769217					
	CC	454 (65)	460 (65)	1.05 (0.99-1.11)	1.05 (0.99-1.12)	0.22
	CT+TT	249 (35)	243 (35)	0.99 (0.91-1.07)	0.98 (0.90-1.07)	
GSR	rs1002149					
	GG	480 (68)	452 (64)	1.01 (0.95-1.07)	1.01 (0.95-1.07)	0.21
	GT+TT	223 (32)	251 (36)	1.06 (0.98-1.15)	1.07 (0.99-1.16)	
SOD1	rs202445					
	AA	460 (65)	490 (70)	0.99 (0.93-1.05)	0.98 (0.93-1.05)	0.016
	AG+GG	243 (35)	213 (33)	1.13 (1.03-1.24)	1.13 (1.03-1.25)	

IRR: incidence rate ratio.

<sup>a</sup> Crude.

<sup>b</sup> Adjusted for parity (parous/nulliparous, number of births, age at first birth), length of school education (low, medium, high), duration of HRT use (years), previous benign breast disease, alcohol intake (10 g/day) and BMI (kg/m<sup>2</sup>) at baseline.

<sup>c</sup> P-value for interaction for adjusted risk estimates.

**Table 5: IRR for BC in relation to the studied polymorphisms and smoking status (present/non-smoker)**

Gene	SNP	Non-smokers n cases/n controls	Present smokers n cases/n controls	Non-smokers IRR <sup>a</sup> (95% CI)	Present smokers IRR <sup>a</sup> (95% CI)	Non-smokers IRR <sup>b</sup> (95% CI)	Present smokers IRR <sup>b</sup> (95% CI)	P-value <sup>c</sup>
CAT	rs1001179							
	GG	264/279	144/130	1.00 (ref.)	1.19 (0.89-1.61)	1.00 (ref.)	1.26 (0.92-1.73)	0.0015
	GA+AA	198/160	97/134	1.35 (1.03-1.77)	0.78 (0.56-1.07)	1.41 (1.07-1.87)	0.83 (0.59-1.17)	
CAT	rs12270780							
	GG	258/251	135/154	1.00 (ref.)	0.86 (0.64-1.15)	1.00 (ref.)	0.89 (0.65-1.21)	0.80
	GA+AA	204/188	106/110	1.04 (0.80-1.35)	0.93 (0.66-1.30)	1.02 (0.78-1.33)	0.96 (0.67-1.36)	
CAT	rs769217							
	CC	306/281	148/179	1.00 (ref.)	0.75 (0.57-1.00)	1.00 (ref.)	0.80 (0.59-1.08)	0.14
	CT+TT	156/158	93/85	0.91 (0.69-1.20)	1.01 (0.73-1.41)	0.93 (0.70-1.24)	1.05 (0.74-1.50)	
GSR	rs1002149							
	GG	322/288	158/164	1.00 (ref.)	0.84 (0.63-1.11)	1.00 (ref.)	0.87 (0.65-1.17)	0.61
	GT+TT	140/151	83/100	0.81 (0.61-1.07)	0.76 (0.54-1.06)	0.82 (0.61-1.10)	0.81 (0.57-1.16)	
SOD1	rs202445							
	AA	314/306	146/184	1.00 (ref.)	0.80 (0.61-1.04)	1.00 (ref.)	0.84 (0.63-1.12)	0.29
	AG+GG	148/133	95/80	1.10 (0.83-1.46)	1.16 (0.81-1.66)	1.14 (0.85-1.53)	1.24 (0.85-1.81)	

IRR: incidence rate ratio.

<sup>a</sup> Crude.

<sup>b</sup> Adjusted for parity (parous/nulliparous, number of births, age at first birth), length of school education (low, medium, high), duration of HRT use (years), previous benign breast disease, alcohol intake (10 g/day) and BMI (kg/m<sup>2</sup>) at baseline.

<sup>c</sup> P-value for interaction for adjusted risk estimates.

this may explain only a minor proportion of observed GSH reduction after acute ethanol intoxication, it is not clear whether such effects are seen at moderate alcohol intake and to what extent this affects GSH availability in breast tissue. A possible inhibitory action of ethanol and/or acetaldehyde on enzymes involved in GSH synthesis has also been hypothesized [48,53]. GSH is critical in maintaining a reduced cellular environment and plays an important role in detoxification processes, including removal of peroxides. Potential GSH depletion combined with impaired GR enzyme activity may impact antioxidant defense, leading to increased carcinogenic potential in the breast tissue. We observed previously that alcohol intake also influences glutathione peroxidase by increasing the activity only in wild-type carriers of the *GPXI* gene and that the *GPXI* Pro198Leu polymorphism may increase BC risk [31]. GSH availability seems therefore potentially important for BC in accordance with the current findings regarding GR.

We were not able to identify other studies examining the relationship between *SOD1* polymorphism, BC risk and potential effect modification by intake of fruit and vegetables. Results from studies investigating the effect of increased intake of fruit and vegetables on SOD activity are inconsistent and the reported effects probably depend both on the presence of specific compounds in the investigated fruit and vegetables as well as the study population. Both negative [54], positive [55,56] and no

[23] effects of intake of specific (or combinations of) fruits and vegetables on SOD enzyme activity have been reported. Our results indicate that fruit and vegetables consumption may affect BC risk differently in carriers of the variant allele of *SOD1* polymorphism compared to wild-type carriers. Per 100 g increment in fruit and vegetable intake, risk of BC increased significantly among variant allele carriers only. The reason for this is not clear, but if fruit and vegetables increase SOD activity, this could potentially lead to increased formation of the highly reactive hydroxyl radicals, leading to oxidative damage and increased risk of BC if not metabolized to less reactive compounds. The increased risk of BC observed in carriers of both the high-activity *SOD1* and low-activity *CAT* (rs1001179) allele could support this explanation. However, whether this is a plausible explanation awaits further studies in larger populations with higher intakes of fruit and vegetables.

Our finding regarding the association between *CAT*/rs1001179 and decreased CAT enzyme activity is consistent with two other studies [33,57]. Compared to the other studied *CAT* polymorphisms (*CAT*/rs12270780 and *CAT*/rs769217), *CAT*/rs1001179 is associated with the largest decline in enzyme activity among 743 postmenopausal women in the present study. This is also shown in the haplotype analysis (Table 9) where the variant allele of *CAT*/rs1001179 is only present on the AGC haplotype which is associated with the largest decrease in CAT

**Table 6: Risk of BC in relation to enzyme activity**

Enzyme activity (U/g Hb)	Cases (n=375)	Controls (n=375)	IRR (95% CI) <sup>a</sup>	IRR (95% CI) <sup>b</sup>	P-value
	n (%)	n (%)			
CAT activity <sup>c</sup>	13.8 (10.6-17.3) <sup>f</sup>	13.7 (10.5-17.6) <sup>f</sup>	0.93 (0.79-1.10)	0.89 (0.75-1.06)	0.20
CAT activity for tertiles <sup>g</sup>					
≤12.8	125 (33)	119 (32)	1.00 (ref.)	1.00 (ref.)	
>12.8-14.4	128 (34)	121 (32)	0.99 (0.68-1.45)	0.93 (0.63-1.38)	0.72
>14.4	122 (33)	135 (36)	0.78 (0.52-1.17)	0.72 (0.47-1.10)	0.13
SOD activity <sup>d</sup>	840 (643-1071) <sup>f</sup>	832 (658-1082) <sup>f</sup>	0.97 (0.82-1.15)	0.94 (0.79-1.12)	0.49
SOD activity for tertiles <sup>g</sup>					
≤795	126 (34)	142 (38)	1.00 (ref.)	1.00 (ref.)	
>795-900	126 (34)	104 (28)	1.51 (0.99-2.59)	1.51 (0.97-2.35)	0.070
>900	123 (33)	129 (34)	1.10 (0.70-1.74)	1.00 (0.62-1.61)	0.99
GR activity <sup>e</sup>	11.4 (9.3-14.0) <sup>f</sup>	11.5 (9.5-14.5) <sup>f</sup>	0.83 (0.68-1.01)	0.83 (0.68-1.02)	0.080
GR activity for tertiles <sup>g</sup>					
≤10.8	128 (34)	127 (34)	1.00 (ref.)	1.00 (ref.)	
>10.8-12.2	126 (34)	122 (33)	1.00 (0.69-1.45)	1.01 (0.69-1.47)	0.97
>12.2	121 (32)	126 (34)	0.95 (0.65-1.37)	0.97 (0.66-1.42)	0.86

Values are expressed as medians with 5th and 95th percentiles. 59 case-control pairs were excluded because one or both in the matched set had missing data on one or more of the potential confounding variables and/or enzyme activities. IRR, incidence rate ratio.

<sup>a</sup> Crude estimates.

<sup>b</sup> The risk estimates for BC are adjusted for parous/nulliparous, number of births, age at first birth, length of school education (low, medium, high), duration of HRT use (years), BMI (kg/m<sup>2</sup>), previous benign breast disease and alcohol intake (10 g/day).

<sup>c</sup> Estimates are per increment in activity of 2 U/g Hb.

<sup>d</sup> Estimates are per increment in activity of 100 U/g Hb.

<sup>e</sup> Estimates are per increment in activity of 2 U/g Hb.

<sup>f</sup> Median (5-95%) levels of enzyme activity (U/g Hb) for cases and controls.

<sup>g</sup> Categories are based on tertiles among both cases and controls.

**Table 7: Associations between erythrocyte enzyme activity and dietary and lifestyle factors**

Dietary and lifestyle factors	CAT activity U/g Hb	P-value	SOD activity U/g Hb	P-value	GR activity U/g Hb	P-value
Alcohol, per 10 g/day	+0.029	0.56	-5.70	0.050	-0.071	0.043
Fruit and vegetables, per 100 g/day	-0.021	0.57	+3.51	0.11	-0.033	0.23
Present smokers compared to non-smokers	-0.22	0.17	+18.83	0.054	+0.033	0.78

The table gives the increase or decrease in enzyme activity per dose.

enzyme activity. Studies on BC risk, however, have mostly failed to find associations between BC and *CAT*/rs1001179 *per se* [reviewed in 54]. In the present study, high CAT enzyme activity was associated with non-significantly lowered BC risk, and variant allele carriers of *CAT*/rs1001179 were at non-significantly increased BC risk.

We found interaction between *CAT*/rs1001179 and smoking status in relation to BC. Among non-smokers, genetically determined lower CAT activity was associated with increased risk of BC, whereas among smokers, homozygous wild-type allele carriers were at non-significantly increased risk. Smoking was though



**Table 8: Associations between the studied genotypes and erythrocyte enzyme activities**

Gene	SNP	Change in enzyme activity measured in U/g Hb (95% CI)		
		Cases (n=386)	Controls (n=357)	All (n=743)
<i>CAT</i>	rs1001179			
	GG	0 (ref.)	0 (ref.)	0 (ref.)
	GA	-1.40 (-1.50;0.99)	-1.79 (-2.23;-1.36)	-1.59 (-1.89;-1.30)
	AA	-3.13 (-3.91;-2.35)	-2.94 (-3.85;-2.03)	-3.05 (-3.64;-2.45)
	<i>P</i> -value <sup>a</sup>	<0.0001	<0.0001	<0.0001
<i>CAT</i>	rs12270780			
	GG	0 (ref.)	0 (ref.)	0 (ref.)
	GA	1.05 (0.62;1.47)	0.93 (0.46;1.40)	0.99 (0.67;1.30)
	AA	1.82 (1.04;2.59)	1.64 (0.47;2.81)	1.75 (1.10;2.40)
	<i>P</i> -value <sup>a</sup>	<0.0001	<0.0001	<0.0001
<i>CAT</i>	rs769217			
	CC	0 (ref.)	0 (ref.)	0 (ref.)
	CT	-0.35 (-0.79;0.10)	-0.89 (-1.39;-0.40)	-0.60 (-0.93;-0.26)
	TT	-0.50 (-1.63;0.62)	-1.35 (-2.72;0.03)	-0.86 (-1.74;0.01)
	<i>P</i> -value <sup>a</sup>	0.25	0.0007	0.0007
<i>GSR</i>	rs1002149			
	GG	0 (ref.)	0 (ref.)	0 (ref.)
	GT	1.69 (1.44;1.95)	2.14 (1.85;2.42)	1.90 (1.71;2.09)
	TT	4.25 (3.49;5.02)	3.83 (3.09;4.56)	4.02 (3.49;4.55)
	<i>P</i> -value <sup>a</sup>	<0.0001	<0.0001	<0.0001
<i>SOD1</i>	rs202445			
	AA	0 (ref.)	0 (ref.)	0 (ref.)
	AG	-3.17 (-31.90;25.56)	7.99 (-22.05;38.03)	2.16 (-18.60;22.92)
	GG	8.90 (-61.96;79.76)	87.71 (12.86;162.56)	46.70 (-4.75;98.16)
	<i>P</i> -value <sup>a</sup>	0.94	0.071	0.21

In this analysis, only individuals with missing values on genotypes and potentials confounders were excluded without regard to the match set.

<sup>a</sup> P-value for trend.

**Table 9: Change in CAT enzyme activity in U/g Hb in relation to haplotype combination**

Haplotype combination	GGC	AGC	P-value <sup>a</sup>	GAC	P-value <sup>a</sup>	GGT	P-value <sup>a</sup>
GGC	0 (ref.)	-1.8	<0.0001	0.3	0.25	-1.0	0.0004
AGC		-3.3	<0.0001	-1.3	<0.0001	-2.7	<0.0001
GAC				0.1	0.68	-0.9	0.0030
GGT						-1.6	<0.0001

<sup>a</sup> p-value for comparison to the wild-type haplotype (G-rs1001179A, G-rs12270780A, C-rs769217T). Variant alleles are in bold.

not associated with CAT activity. Taken together, the results may suggest that CAT genetically determined high enzyme activity is protective of BC especially among non-smokers. While smoking had no statistically significant effect on CAT enzyme activity, smoking may

change the cellular oxidant/antioxidant environment due to the presence of other compounds in the smoke, thereby masking the effect of the polymorphism we report among non-smokers. Whether the inconsistent effects observed among smokers and non-smokers are linked to

**Table 10: IRR for BC for combinations of *CAT*/rs1001179 and *SOD1*/rs202445 genotypes**

<i>CAT</i> /rs1001179	IRR (95% CI) <sup>a</sup>		IRR (95% CI) <sup>b</sup>		<i>P</i> -value <sup>c</sup>
	<i>SOD1</i> /rs202445				
	AA	AG+GG	AA	AG+GG	
GG	1.00 (ref.)	1.12 (0.83-1.50)	1.00 (ref.)	1.12 (0.83-1.53)	0.27
GA+AA	0.96 (0.74-1.23)	1.31 (0.94-1.83)	0.98 (0.75-1.26)	1.43 (1.01-2.01)	

IRR: incidence rate ratio.

<sup>a</sup> Crude.

<sup>b</sup> Adjusted for parous/nulliparous, number of births, age at first birth, length of school education (low, medium, high), duration of HRT use (years), BMI (kg/m<sup>2</sup>), previous benign breast disease and alcohol intake (10 g/day).

<sup>c</sup> *P*-value for interaction on a multiplicative scale.

the possible anti-estrogenic effect of smoking reported in some studies [59,60] is not clear but needs further investigation.

We used a prospective, nested case-control design, which together with complete follow-up minimizes selection bias. In addition, information on life style factors was collected at enrolment, which reduces the risk for differential misclassification between cases and controls. The study is fairly large to study main effects, it is homogenous and alcohol consumption is relatively high in the DCH cohort [61] making it suitable for studying gene-environment interactions. However, Danes including the Danish women in the present study have a relatively low intake of fruit and vegetables (Table 1), and therefore, the present study may have limited statistical power to detect effects of fruits and vegetables consumption on antioxidant enzyme activities. The genes were carefully selected based on known and predicted functionality. Nevertheless, we are aware that our study may not be large enough for some of the gene environment interactions, although we have previously found gene-environment interactions for *PPARG* and alcohol intake and *ADH* and alcohol intake in relation to BC in the present cohort [40,41].

Neither enzyme activities measured once at study entry nor genetically determined differences in enzyme activities were associated with risk of BC. There are two possible interpretations; either that antioxidant activity is not involved in breast carcinogenesis. Alternatively, genetically determined variations are small compared to the influence of lifestyle factors. However, smoking, alcohol intake and fruit and vegetable intake only correlated with the measured enzyme activities to a very limited extent. Thus, the genetically determined changes in the enzyme activities were larger than the effects of the lifestyle factors studied here. Our results therefore suggest that the antioxidant enzyme activities included here are not major determinants of BC risk.

## MATERIALS AND METHODS

### Subjects

The subjects were selected from the ongoing Danish DCH cohort study. The present study group has been described previously [40,41]. In short, 79,729 women aged 50–64 years, born in Denmark, living in the Copenhagen or Aarhus areas and having no previous cancers at the time of invitation were invited to participate in the study between December 1993 and May 1997. A total of 29,875 women accepted the invitation, corresponding to 37% of the invited women.

Study participants were followed up for diagnosis of BC from date of entry until either the date of diagnosis of cancer using record linkage to the Danish Cancer Registry until 2003 and afterwards by linkage to the Danish Pathology Databank, date of death, date of emigration, or April 27th, 2006, whichever came first. A total of 975 women were diagnosed with BC during the follow-up period. For each case, one matched control was selected [40,41]. The control was cancer-free at the exact age at diagnosis of the case and was further matched on age at inclusion into the cohort (half-year intervals), use of HRT (current/former/never) and on certainty of postmenopausal status (known/probably postmenopausal) upon inclusion into the cohort [40,41]. 208 individuals were excluded because of failed genotyping or no buffy coat was available. Additionally 82 individuals were excluded because of missing information about one or more of the potential confounding variables. 254 individuals were excluded because of a missing partner in the case-control pair, due to the above mentioned exclusions leaving 703 pairs for data analyses.

### Data on covariates

From food frequency and lifestyle questionnaires, we obtained information on duration of school education,

smoking status, HRT use, birth pattern (number of births and age at first birth), alcohol intake and diet. Body mass index (BMI) was computed based on measurements of height and weight at enrolment. Intake of alcohol was inferred from the food-frequency questionnaire and lifestyle questionnaire as described in details in [40,41]. Abstainers were defined as those who reported no intake of alcohol on the food-frequency questionnaire and no drinking occasions on the lifestyle questionnaire. Findings on all known risk factors have been reported previously for both the entire DCH cohort, for a subset of the present study, and for the present study group [40,42–46].

### Blood sampling and storage

From non-fasting participants a total of 30 ml blood was collected in citrated (2 x 10 ml) and plain (1 x 10 ml) Venojects from each participant. Plasma, serum, lymphocytes and erythrocytes were isolated and frozen at -20°C within 2 hours. At the end of the day of collection, all samples were stored in liquid nitrogen, at -150°C.

### Genotyping

DNA was isolated from frozen lymphocytes as described [62]. Generally, 100 mg DNA was obtained from 10<sup>7</sup> lymphocytes. All polymorphisms were genotyped by KBioscience (KBioscience, Hoddesdon, United Kingdom) by PCR-based KASPTM genotyping assay (<http://www.lgcgenomics.com/>). To confirm reproducibility, genotyping was repeated for 10 % of the samples yielding 100% identical genotypes.

### Selection of polymorphisms

Common, functional polymorphisms in *SOD1*, *CAT* and *GSR* were chosen with minor allele frequencies between 0.31 and 0.44 which is considered ideal when studying gene-environment interactions [63–65]. Functionality was either based on a literature search or using the <http://manticore.niehs.nih.gov/snpinfo/snpfunc.htm> website [66], which is a web-based tool that predicts functionality of SNPs. *SOD1*/rs202445 is located in the regulatory region of the promotor [67]. *GSR*/rs1002149 and *CAT*/rs1001179 are also located in the promoter region [58,67] at a transcription factor binding site [66]; and *CAT*/rs1001179 correlates with catalase activity [33,57,68]. *CAT*/rs769217 is located in exon 9 [58] at an exonic splicing site [66]; and *CAT*/rs12270780 is located in intron 2 ([http://www.ncbi.nlm.nih.gov/projects/SNP/snp\\_ref.cgi?rs=12270780](http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=12270780)) at a transcription factor binding site [66].

### Erythrocyte enzyme activities

In a subset of the present cohort comprising 434 case-control pairs, SOD, CAT and GR activities were determined spectrophotometrically in erythrocyte lysates on a Cobas Mira analyzer (F. Hoffmann-La Roche Ltd, Basel, Switzerland) according to Wheeler et al. [69]. This subset has been described in details elsewhere [31]. Intra- and interday CVs were 2,8% and 4,7% for GR, 6,8% and 9,7% for SOD and 4,6% and 9% for CAT.

### Statistical analyses

Deviation from Hardy-Weinberg equilibrium was assessed using a Chi square test.

Due to the study design using incidence density sampling of controls with match on age at diagnosis, matched logistic regression analyses leads to estimation of BC incidence rate ratio (IRR) [70] corresponding to a Cox proportional hazard model for the full cohort with age as the time axis. The associations between genotype, enzyme activity and BC are presented as crude IRR as well as adjusted for potential BC risk factors. Two-sided 95% confidence intervals (CI) for the IRR were calculated based on Wald's test of the Cox regression parameter, i.e. on the log RR scale. All models were adjusted for baseline values of risk factors for BC such as parity (entered as two variables; parous/nulliparous and number of births), age at first birth, length of school education (low, medium and high), duration of HRT use, alcohol intake and BMI. IRR was calculated separately for heterozygous and homozygous variant allele carriers. For all the SNPs, variant allele carriers were subsequently grouped for interaction analyses to improve the statistical power since no recessive effects were observed. For the different genetic variations, we investigated interactions with alcohol intake, smoking, and fruit and vegetables, using the likelihood ratio test.

A covariance model was used to determine the effects of fruits and vegetables, intake of alcohol and smoking on enzyme activity according to genotype. Enzyme activity was found to be normally distributed among the participants, and hence, the activity was entered untransformed as the dependent variable in the covariate models.

The procedures PHREG (Proportional Hazard Regression) and GLM (General Linear Model) in SAS, release 9.3; SAS Institute, (Cary, NC) were used for the matched logistic regression analyses and the covariance analyses, respectively.

### Ethics statement

All participants gave verbal and written informed consent before enrolment to the study. The DCH study was approved by the regional Ethical Committees on

## Abbreviations

BC: breast cancer; BMI: body mass index; CAT: catalase; CI: confidence intervals; DCH cohort: “diet, cancer and health” cohort; GR: glutathione reductase; HRT: hormone replacement therapy; IRR: incidence rate ratio; ROS: reactive oxygen species; SNP: single nucleotide polymorphism; SOD: superoxide dismutase.

## Author contributions

TIK participated in the design of the study, performed statistical analyses and drafted the manuscript. UV participated in the design of the study and participated in drafting the manuscript. LOD conceived the study. AT designed the case-control study and contributed with materials and analysis tools. GRH participated in the design of the study, carried out analyses of erythrocyte enzyme activities and participated in drafting the manuscript. All authors read and approved the final manuscript.

## ACKNOWLEDGMENTS

We thank Vibeke Kegel, Nick Martinussen and Katja Boll for excellent technical support; and Jane Christensen and Rikke Kart Jacobsen for statistical consulting.

## CONFLICTS OF INTEREST

The authors declare that they have no competing interests.

## FUNDING

The project was supported by a PhD stipend from the Danish Research Councils in the programme ‘An integrated approach to risk-benefit assessment of human health effects of food and food contaminants’ (Forskeruddannelse 2009-10), and by a Mobility PhD grant (09-06 7572) from the Danish Council for Independent Research ([www.ufm.dk](http://www.ufm.dk)).

## REFERENCES

1. Engholm G, Ferlay J, Christensen N, Johannesen TB, Klint Å, Kötum JE, Milner MC, Ólafsdóttir E, Pukkala E, Storm HH. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 5.1. Association of the Nordic Cancer Registries. Danish Cancer Society. 2012. Available from <http://www.ancr.nu>
2. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med*. 2000; 343: 78–85.
3. Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, West DW, Wu-Williams AH, Kolonel LN, Horn-Ross PL, Rosenthal JF, Hyer MB. Migration patterns and breast cancer risk in Asian-American women. *J Natl Cancer Inst*. 1993; 85: 1819–27.
4. Deapen D, Liu L, Perkins C, Bernstein L, Ross RK. Rapidly rising breast cancer incidence rates among Asian-American women. *Int J Cancer*. 2002; 99: 747–50.
5. Song M, Lee KM, Kang D. Breast cancer prevention based on gene-environment interaction. *Mol Carcinog*. 2011; 50: 280–90.
6. Dumitrescu RG, Cotarla I. Understanding breast cancer risk -- where do we stand in 2005? *J Cell Mol Med*. 2005; 9: 208–21.
7. Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. *Mutat Res*. 2003; 544: 9–41.
8. Pelucchi C, Tramacere I, Boffetta P, Negri E, La VC. Alcohol consumption and cancer risk. *Nutr Cancer*. 2011; 63: 983–90.
9. Boffetta P, Hashibe M. Alcohol and cancer. *Lancet Oncol*. 2006; 7: 149–56.
10. Singletary KW, Gapstur SM. Alcohol and breast cancer. *JAMA*. 2001; 286: 2143–51.
11. Castro GD, Castro JA. Alcohol drinking and mammary cancer: pathogenesis and potential dietary preventive alternatives. *World J Clin Oncol*. 2014; 5: 713–29.
12. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. *Biochem J*. 1996; 313: 17–29.
13. Ambrosone CB, Freudenheim JL, Thompson PA, Bowman E, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Shields PG. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. *Cancer Res*. 1999; 59: 602–6.
14. Ambrosone CB. Oxidants and antioxidants in breast cancer. *Antioxid Redox Signal*. 2000; 2: 903–17.
15. Cerutti PA. Oxy-radicals and cancer. *Lancet*. 1994; 344: 862–3.
16. Cerutti PA, Trump BF. Inflammation and oxidative stress in carcinogenesis. *Cancer cells*. 1991; 3: 1–7.
17. Mates JM, Perez-Gomez C, Nunez de Castro I. Antioxidant enzymes and human diseases. *Clin Biochem*. 1999; 32: 595–603.
18. McCullough LE, Santella RM, Cleveland RJ, Bradshaw PT, Millikan RC, North KE, Olshan AF, Eng SM, Ambrosone CB, Ahn J, Steck SE, Teitelbaum SL, Neugut AI, et al. Polymorphisms in oxidative stress genes, physical activity, and breast cancer risk. *Cancer Causes Control*. 2012; 23: 1949–58.



19. Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). *Free Radic Res.* 1999; 31: 261–72.
20. Halliwell B. Oxidative stress and cancer: have we moved forward? *Biochem J.* 2007; 401: 1–11.
21. Young JF, Dragsted LO, Daneshvar B, Lauridsen ST, Hansen M, Sandström B. The effect of grape-skin extract on oxidative status. *Br J Nutr.* 2000; 84: 505–13.
22. Nielsen SE, Young JF, Daneshvar B, Lauridsen ST, Knuthsen P, Sandström B, Dragsted LO. Effect of parsley (*Petroselinum crispum*) intake on urinary apigenin excretion, blood antioxidant enzymes and biomarkers for oxidative stress in human subjects. *Br J Nutr.* 1999; 81: 447–55.
23. Dragsted LO, Pedersen A, Hermetter A, Basu S, Hansen M, Haren GR, Kall M, Breinholt V, Castenmiller JJ, Stagsted J, Jakobsen J, Skibsted L, Rasmussen SE, et al. The 6-a-day study: effects of fruit and vegetables on markers of oxidative stress and antioxidative defense in healthy nonsmokers. *Am J Clin Nutr.* 2004; 79: 1060–72.
24. Young JF, Nielsen SE, Haraldsdóttir J, Daneshvar B, Lauridsen ST, Knuthsen P, Crozier A, Sandström B, Dragsted LO. Effect of fruit juice intake on urinary quercetin excretion and biomarkers of antioxidative status. *Am J Clin Nutr.* 1999; 69: 87–94.
25. Gandini S, Merzenich H, Robertson C, Boyle P. Meta-analysis of studies on breast cancer risk and diet: the role of fruit and vegetable consumption and the intake of associated micronutrients. *Eur J Cancer.* 2000; 36: 636–46.
26. Howe GR, Hirohata T, Hislop TG, Iscovich JM, Yuan JM, Katsouyanni K, Lubin F, Marubini E, Modan B, Rohan T. Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. *J Natl Cancer Inst.* 1990; 82: 561–9.
27. Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. *Am J Clin Nutr.* 2003; 78: 559S–569S.
28. Smith-Warner SA, Spiegelman D, Yaun SS, Adami HO, Beeson WL, van den Brandt PA, Folsom AR, Fraser GE, Freudenheim JL, Goldbohm RA, Graham S, Miller AB, Potter JD, et al. Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. *JAMA.* 2001; 285: 769–76.
29. Aune D, Chan DS, Vieira AR, Rosenblatt DA, Vieira R, Greenwood DC, Norat T. Fruits, vegetables and breast cancer risk: a systematic review and meta-analysis of prospective studies. *Breast Cancer Res Treat.* 2012; 134: 479–93.
30. Nowell SA, Ahn J, Ambrosone CB. Gene-nutrient interactions in cancer etiology. *Nutr Rev.* 2004; 62: 427–38.
31. Ravn-Haren G, Olsen A, Tjønneland A, Dragsted LO, Nexø BA, Wallin H, Overvad K, Raaschou-Nielsen O, Vogel U. Associations between GPX1 Pro198Leu polymorphism, erythrocyte GPX activity, alcohol consumption and breast cancer risk in a prospective cohort study. *Carcinogenesis.* 2006; 27: 820–5.
32. Li Y, Ambrosone CB, McCullough MJ, Ahn J, Stevens VL, Thun MJ, Hong CC. Oxidative stress-related genotypes, fruit and vegetable consumption and breast cancer risk. *Carcinogenesis.* 2009; 30: 777–84.
33. Ahn J, Gammon MD, Santella RM, Gaudet MM, Britton JA, Teitelbaum SL, Terry MB, Nowell S, Davis W, Garza C, Neugut AI, Ambrosone CB. Associations between breast cancer risk and the catalase genotype, fruit and vegetable consumption, and supplement use. *Am J Epidemiol.* 2005; 162: 943–52.
34. Terry PD, Goodman M. Is the association between cigarette smoking and breast cancer modified by genotype? A review of epidemiologic studies and meta-analysis. *Cancer Epidemiol Biomarkers Prev.* 2006; 15: 602–11.
35. Kumar K, Thangaraju M, Sachdanandam P. Changes observed in antioxidant system in the blood of postmenopausal women with breast cancer. *Biochem Int.* 1991; 25: 371–80.
36. Kumaraguruparan R, Subapriya R, Kabalimoorthy J, Nagini S. Antioxidant profile in the circulation of patients with fibroadenoma and adenocarcinoma of the breast. *Clin Biochem.* 2002; 35: 275–9.
37. Pawlowicz Z, Zachara BA, Trafikowska U, Maciag A, Marchaluk E, Nowicki A. Blood selenium concentrations and glutathione peroxidase activities in patients with breast cancer and with advanced gastrointestinal cancer. *J Trace Elem Electrolytes Health Dis.* 1991; 5: 275–7.
38. Abiaka C, Al-Awadi F, Al-Sayer H, Gulshan S, Behbehani A, Farghally M. Activities of erythrocyte antioxidant enzymes in cancer patients. *J Clin Lab Anal.* 2002; 16: 167–71.
39. Meplan C, Dragsted LO, Ravn-Haren G, Tjønneland A, Vogel U, Hesketh J. Association between polymorphisms in glutathione peroxidase and selenoprotein P genes, glutathione peroxidase activity, HRT use and breast cancer risk. *PLoS One.* 2013; 8: e73316.
40. Benzon LS, Vogel U, Christensen J, Hansen RD, Wallin H, Overvad K, Tjønneland A, Tolstrup J. Interaction between ADH1C Arg(272)Gln and alcohol intake in relation to breast cancer risk suggests that ethanol is the causal factor in alcohol related breast cancer. *Cancer Lett.* 2010; 295: 191–7.
41. Petersen RK, Larsen SB, Jensen DM, Christensen J, Olsen A, Loft S, Nellemann C, Overvad K, Kristiansen K, Tjønneland A, Vogel U. PPARgamma-PGC-1alpha activity is determinant of alcohol related breast cancer. *Cancer Lett.* 2012; 315: 59–68.
42. Vogel U, Christensen J, Nexø BA, Wallin H, Friis S, Tjønneland A. Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast



- cancer in a prospective study of Danes. *Carcinogenesis*. 2007; 28: 427–34.
43. Tjønneland A, Christensen J, Thomsen BL, Olsen A, Stripp C, Overvad K, Olsen JH. Lifetime alcohol consumption and postmenopausal breast cancer rate in Denmark: a prospective cohort study. *J Nutr*. 2004; 134: 173–8.
  44. Friis S, Thomassen L, Sorensen HT, Tjønneland A, Overvad K, Cronin-Fenton DP, Vogel U, McLaughlin JK, Blot WJ, Olsen JH. Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. *Eur J Cancer Prev*. 2008; 17: 88–96.
  45. Tjønneland A, Thomsen BL, Stripp C, Christensen J, Overvad K, Møllemaer L, Grønbaek M, Olsen JH. Alcohol intake, drinking patterns and risk of postmenopausal breast cancer in Denmark: a prospective cohort study. *Cancer Causes Control*. 2003; 14: 277–84.
  46. Tjønneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M, Møllemaer L. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. *Cancer*. 2004; 100: 2328–37.
  47. Kopp TI, Jensen DM, Ravn-Høren G, Cohen A, Sommer HM, Dragsted LO, Tjønneland A, Høgarth DM, Vogel U. Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial. *BMC Cancer*. 2016; 16: 283.
  48. Fanelli SL, Maciel ME, Díaz Gómez MI, Delgado de Layño AM, Bietto FM, Castro JA, Castro GD. Further studies on the potential contribution of acetaldehyde accumulation and oxidative stress in rat mammary tissue in the alcohol drinking promotion of breast cancer. *J Appl Toxicol*. 2011; 31: 11–9.
  49. Dong X, Liu H, Chen F, Li D, Zhao Y. MiR-214 promotes the alcohol-induced oxidative stress via down-regulation of glutathione reductase and cytochrome P450 oxidoreductase in liver cells. *Alcohol Clin Exp Res*. 2014; 38: 68–77.
  50. Das SK, Hiran KR, Mukherjee S, Vasudevan DM. Oxidative stress is the primary event: effects of ethanol consumption in brain. *Indian J Clin Biochem*. 2007; 22: 99–104.
  51. Cederbaum AI, Lu Y, Wu D. Role of oxidative stress in alcohol-induced liver injury. *Arch Toxicol*. 2009; 83: 519–48.
  52. Videla LA, Valenzuela A. Alcohol ingestion, liver glutathione and lipoperoxidation: metabolic interrelations and pathological implications. *Life Sci*. 1982; 31: 2395–407.
  53. Videla L, Guerri C. Glutathione and alcohol. In: Viña J, editor. *Glutathione: Metabolism and Physiological Functions*. CRC Press; 1990. 57–67.
  54. Zheng J, Rautiainen S, Morgenstern R, Wolk A. Relationship between plasma carotenoids, fruit and vegetable intake, and plasma extracellular superoxide dismutase activity in women: different in health and disease? *Antioxid Redox Signal*. 2011; 14: 9–14.
  55. Ghavipour M, Sotoudeh G, Ghorbani M. Tomato juice consumption improves blood antioxidative biomarkers in overweight and obese females. *Clin Nutr*. 2015; 34: 805–9.
  56. Avci A, Atli T, Ergüder IB, Varli M, Devrim E, Aras S, Durak I. Effects of garlic consumption on plasma and erythrocyte antioxidant parameters in elderly subjects. *Gerontology*. 2008; 54: 173–6.
  57. Nadif R, Mintz M, Jedlicka A, Bertrand JP, Kleeberger SR, Kauffmann F. Association of CAT polymorphisms with catalase activity and exposure to environmental oxidative stimuli. *Free Radic Res*. 2005; 39: 1345–50.
  58. Crawford A, Fasset RG, Geraghty DP, Kunde DA, Ball MJ, Robertson IK, Coombes JS. Relationships between single nucleotide polymorphisms of antioxidant enzymes and disease. *Gene*. 2012; 501: 89–103.
  59. Windham GC, Mitchell P, Anderson M, Lasley BL. Cigarette smoking and effects on hormone function in premenopausal women. *Environ Health Perspect*. 2005; 113: 1285–90.
  60. Michnovicz JJ, Herschopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. *N Engl J Med*. 1986; 315: 1305–9.
  61. Sieri S, Agudo A, Kesse E, Klipstein-Grobusch K, San-Jose B, Welch AA, Krogh V, Luben R, Allen N, Overvad K, Tjønneland A, Clavel-Chapelon F, Thiebaut A, et al. Patterns of alcohol consumption in 10 European countries participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) project. *Public Health Nutr*. 2002; 5: 1287–96.
  62. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res*. 1988; 16: 1215.
  63. Luan JA, Wong MY, Day NE, Wareham NJ. Sample size determination for studies of gene-environment interaction. *Int J Epidemiol*. 2001; 30: 1035–40.
  64. Foppa I, Spiegelman D. Power and sample size calculations for case-control studies of gene-environment interactions with a polytomous exposure variable. *Am J Epidemiol*. 1997; 146: 596–604.
  65. Wong MY, Day NE, Luan JA, Chan KP, Wareham NJ. The detection of gene-environment interaction for continuous traits: should we deal with measurement error by bigger studies or better measurement? *Int J Epidemiol*. 2003; 32: 51–7.
  66. Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. *Nucleic Acids Res*. 2009; 37: W600–5.
  67. Udler M, Maia AT, Cebrian A, Brown C, Greenberg D, Shah M, Caldas C, Dunning A, Easton D, Ponder B, Pharoah P. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. *J Clin Oncol*. 2007; 25: 3015–23.
  68. Forsberg L, Lyrenas L, de Faire U, Morgenstern R. A common functional C-T substitution polymorphism in the

- promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. *Free Radic Biol Med.* 2001; 30: 500–5.
69. Wheeler CR, Salzman JA, Elsayed NM, Omaye ST, Korte DW Jr. Automated assays for superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activity. *Anal Biochem.* 1990; 184: 193–9.
70. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. *Biometrics.* 1978; 34: 541–54.